



Universiteit
Leiden
The Netherlands

Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial (vol 42, 10.1200/JCO-24-01883, 2024)

Goto, K.; Goto, Y.; Kubo, T.; Ninomiya, K.; Kim, S.W.; Planchard, D.; ... ; Jänne, P.A.

Citation

Goto, K., Goto, Y., Kubo, T., Ninomiya, K., Kim, S. W., Planchard, D., ... Jänne, P. A. (2024). Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial (vol 42, 10.1200/JCO-24-01883, 2024). *Journal Of Clinical Oncology*, 42(30), 3635-3635.
doi:10.1200/JCO-24-01883

Version: Publisher's Version

License: [Licensed under Article 25fa Copyright Act/Law \(Amendment Taverne\)](#)

Downloaded from: <https://hdl.handle.net/1887/4213108>

Note: To cite this publication please use the final published version (if applicable).

Erratum: Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

The November 1, 2023, article by Goto et al entitled “Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial” (*J Clin Oncol* [10.1200/JCO.23.01361](https://doi.org/10.1200/JCO.23.01361)) was published with an error.

In Table 1, under the row heading Race, between White and Other, there should have been an additional row with the heading **Black or African American.**” The values for this row should have been entered as follows:

T-DXd 5.4 mg/kg: 0

T-DXd 6.4 mg/kg: 2 (4.0)

This has been corrected as of September 13, 2024. The authors apologize for the error.

DOI: <https://doi.org/10.1200/JCO-24-01883>
